Protocol RH-1-002: A phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic dose-escalation study of RH-1 administered as a 3-hour intravenous infusion in patients with solid tumors or non-Hodgkin's lymphoma

Trial Profile

Protocol RH-1-002: A phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic dose-escalation study of RH-1 administered as a 3-hour intravenous infusion in patients with solid tumors or non-Hodgkin's lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 May 2013

At a glance

  • Drugs RH 1 (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Allos Therapeutics
  • Most Recent Events

    • 06 May 2009 Actual patient number (12) added as reported by ClinicalTrials.gov.
    • 04 Mar 2009 Estimated patient numbers amended from 83 to 60 as reported by ClinicalTrials.gov.
    • 04 Mar 2009 Status changed from active, no longer recruiting to discontinued, asreported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top